An Early Phase 1 interventional study of Placebo Ophthalmic Solution (Vehicle) and JN002 Ophthalmic Solution (0.05 mg/mL) in Dry Eye, sponsored by Eye & ENT Hospital of Fudan University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-01.
Sponsored by Eye & ENT Hospital of Fudan University · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies in Dry Eye Syndromes with a site in China — 28 open to participants now, 30 under way, 3 of them phase 3. Dry Eye Syndromes · China.
Among the 106 studies in Dry Eye Syndromes with a site in China, this one is the 67th largest by planned enrollment of the 83 interventional ones that give a count, is one of 6 that started in 2025, is one of 7 in phase 1, reaches primary completion later than 12 of the 29 other live ones, and was the 93rd registered.
1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →28 of the 106 studies in Dry Eye Syndromes with a site in China are open now. Recruiting first, the newest first:
Ocumension Therapeutics (Suzhou) Co., Ltd · Sites in China
Ages 30–75
The First Affiliated Hospital of Xiamen University · Sites in China
Ages 18+
Shanghai Changzheng Hospital · Sites in China
Ages 18–70 · Healthy volunteers
Jin Yang · Sites in China
Chen Wei · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 11 · Phase 3 11 · Phase 4 9
First in 2010; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 60 across 1,132 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 80 across the 83 interventional studies, 100 across the 23 observational. Of the 50 that completed or were terminated, 3 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 106 have an industry lead sponsor. The 10 most frequent:
Eye & ENT Hospital of Fudan University is the lead sponsor of 127 studies on the registry; 71 are open to participants now.
Eye & ENT Hospital of Fudan University has 4 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
8 of the studies in Dry Eye Syndromes with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06360133Phase 3VivaVision Biotech, IncStudy of 5% VVN001 Ophthalmic Solution in Dry Eye Disease | 2027-04-30 |
| NCT07940452Eye & ENT Hospital of Fudan UniversityA Novel Eye Wash Solution for DED Treatment | 2026-11 |
| NCT07623382The First Affiliated Hospital of Xiamen UniversityHuman Umbilical Cord Mesenchymal Stem Cell-derived Small Extracellular Vesicles for the Treatment of Dry Eye Disease | 2026-11-30 |
| NCT05605314Peking University Third HospitalClinical Cohort Study in Patients With Different Subtypes of Primary Sjogren Syndrome Related Dry Eye | 2027-01-01 |
| NCT07679685Beijing Tongren HospitalPerfluorohexyloctane Eye Drops vs. Sodium Hyaluronate for Video Display Terminal-Associated Dry Eye | 2027-02-28 |
Add all 8 to your calendar (.ics) → With an account.
Among the 106 studies in Dry Eye Syndromes with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a first-in-human, single-center, randomized, double-blind, placebo-controlled clinical trial designed to:·Evaluate the efficacy of JN002 Ophthalmic Solution in treating dry eye disease (DED)·Assess the safety of JN002 Ophthalmic SolutionResearchers will compare three groups-placebo (vehicle), low-dose JN002 (0.05 mg/mL), and high-dose JN002 (0.1 mg/mL)-to evaluate whether JN002 Ophthalmic Solution improves DED outcomes and to assess its safety profile relative to placebo.Participants will:·Complete a baseline assessment (V0) including ocular exams, OSDI questionnaire, and systemic evaluation;·Administer the assigned study medication three times daily (1 drop per eye per administration);·Attend three follow-up visits (V1: 7±2 days, V2: 14±2 days, V3: 28±2 days post-treatment initiation) for ocular assessments, symptom queries, and adherence checks;·Undergo a full repeat of baseline assessments at V3 to evaluate treatment effects and safety profile
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo ophthalmic solution
Drug: Placebo Ophthalmic Solution (Vehicle)
JN002 Ophthalmic Solution at a concentration of 0.05 mg/mL
Drug: JN002 Ophthalmic Solution (0.05 mg/mL)
JN002 Ophthalmic Solution at a concentration of 0.1 mg/mL
Drug: JN002 Ophthalmic Solution (0.1 mg/mL)
Placebo ophthalmic solution (vehicle without active ingredient JN002), administered three times daily (1 drop per eye per dose) for 28 ± 2 consecutive days
JN002 Ophthalmic Solution at a concentration of 0.05 mg/mL, administered three times daily (1 drop per eye per dose) for 28 ± 2 consecutive days
JN002 Ophthalmic Solution at a concentration of 0.1 mg/mL, administered three times daily (1 drop per eye per dose) for 28 ± 2 consecutive days
Corneal Fluorescein Staining score
Change from baseline in Corneal Fluorescein Staining (CFS) score at the 7±2 days, 14±2 days and 28±2 days follow-up. CFS is evaluated following the guidelines from the National Eye Institute: the corneal surface is divided into five regions (central, superior, inferior, nasal, temporal), with each region assigned a score ranging from 0 to 3, resulting in a total possible score of 0 to 15-higher scores indicate more severe corneal epithelial damage and a worse clinical outcome.
Time frame: Baseline, 7±2 days, 14±2 days and 28 ± 2 days
Ocular Surface Disease Index score
Change from baseline in Ocular Surface Disease Index (OSDI) score at the 7±2 days, 14±2 days and 28±2 days follow-up. OSDI is assessed via a 12-item self-reported questionnaire, where raw scores are converted to a standardized 0-100 scale through a specific calculation, with higher scores indicating more severe ocular surface disease symptoms.
Time frame: Baseline, 7±2 days, 14±2 days and 28±2 days
Schirmer I test
Change from baseline in Schirmer I test result (measuring aqueous tear secretion) at the 28±2 days follow-up.
Time frame: Baseline and 28 ± 2 days
Tear meniscus height
Change from baseline in tear meniscus height at the 28±2 days follow-up.
Time frame: Baseline and 28 ± 2 days
Non-invasive tear film break-up time
Change from baseline in non-invasive tear film break-up time (measured via Keratograph 5M) at the 28±2 days follow-up.
Time frame: Baseline and 28 ± 2 days
Tear inflammatory cytokines
Change from baseline in tear inflammatory cytokines (IL-1β, IL-6, IL-17A, TNF-α, INF-γ) levels at the 28±2 days follow-up.
Time frame: Baseline and 28 ± 2 days
Corneal dendritic cell density
Change from baseline in corneal dendritic cell density at the 28±2 days follow-up, assessed and quantified via in vivo corneal confocal microscopy (IVCM)-a specialized imaging tool for ocular surface evaluation.
Time frame: Baseline and 28 ± 2 days
Best-corrected visual acuity
Best-corrected visual acuity assessed at baseline, 7±2 days, 14±2 days, and 28±2 days.
Time frame: Baseline, 7 ± 2 days, 14 ± 2 days, and 28 ± 2 days
Intraocular pressure
Intraocular pressure assessed at baseline, 7±2 days, 14±2 days, and 28±2 days.
Time frame: Baseline, 7±2 days, 14±2 days, and 28±2 days.
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Mar 2026, 4 months after the start.
Of 34 phase 1 interventional studies under Dry Eye Syndromes, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's planned 4 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eye & ENT Hospital of Fudan University →